Black Diamond Therapeutics, Inc. (BDTX) — Financial statements
Income statement, balance sheet, and cash flow for Black Diamond Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 70 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.33 | 0.00↓100.0% | 0.44 | 0.00 | 0.00 | |
| Gross Profit | 70 | 0.00↑100.0% | -0.44 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 34↓34.6% | 51↓12.9% | 59↓8.6% | 64↓33.5% | 97 | |
| General & Administrative Expenses | 17↓39.7% | 27↑1.3% | 27↓4.5% | 28↓5.5% | 30 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↓39.7% | 27↑1.3% | 27↓4.5% | 28↓5.5% | 30 | |
| Other Expenses | -0.33 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 50↓36.8% | 79↓8.4% | 86↓7.3% | 93↓26.8% | 127 | |
| Total Costs & Expenses | 50↓36.4% | 79↓8.9% | 86↓6.9% | 93↓26.8% | 127 | |
| Operating Results | ||||||
| Operating Income | 20↑125.2% | -79↑8.9% | -86↑6.9% | -93↑26.8% | -127 | |
| Depreciation & Amortization | 0.33↓5.2% | 0.34↓21.5% | 0.44↓14.0% | 0.51↑147.8% | 0.21 | |
| EBITDA | 20↑125.7% | -78↑8.8% | -86↑6.8% | -92↑27.1% | -127 | |
| EBIT | 20↑125.2% | -79↑8.9% | -86↑6.9% | -93↑26.8% | -127 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↑86.1% | 2↑13.4% | 2↓5.3% | 2↓41.4% | 3 | |
| Interest Income | 4↑86.1% | 2↑13.4% | 2↓5.3% | 2↓41.4% | 3 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↓72.6% | 9↑126.6% | 4↑142.2% | 2↑30.0% | 1 | |
| Income Before Tax | 22↑132.1% | -70↑15.5% | -82↑9.6% | -91↑27.4% | -126 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 22↑132.1% | -70↑15.5% | -82↑9.6% | -91↑27.4% | -126 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 22↑132.1% | -70↑15.5% | -82↑9.6% | -91↑27.4% | -126 | |
| Bottom-Line Net Income | 22↑132.1% | -70↑15.5% | -82↑9.6% | -91↑27.4% | -126 | |
| EPS (Basic) | 0.39↑130.7% | -1.27↑32.4% | -1.88↑25.4% | -2.52↑27.4% | -3.47 | |
| EPS (Diluted) | 0.39↑130.7% | -1.27↑32.4% | -1.88↑25.4% | -2.52↑27.4% | -3.47 | |
| Weighted Average Shares | 57↑3.3% | 55↑25.2% | 44↑21.3% | 36↑0.1% | 36 | |
| Weighted Average Diluted Shares | 58↑4.6% | 55↑25.2% | 44↑21.3% | 36↑0.1% | 36 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.